A multicenter evaluation of external outflow graft obstruction with a fully magnetically levitated left ventricular assist device
Copyright © 2022 The American Association for Thoracic Surgery. All rights reserved..
BACKGROUND: The HeartMate 3 (HM 3; Abbott) left ventricular assist device (LVAD) has improved hemocompatibility-related adverse outcomes. In sporadic cases, external compression of the outflow graft causing obstruction (eOGO) can result from substance accumulation between the outflow graft and its bend relief. We sought to evaluate the prevalence, course, and clinical implications of eOGO in an international study.
METHODS: A multicenter retrospective analysis of HM 3 LVADs implanted between November 2014 and April 2021 (n = 2108) was conducted across 17 cardiac centers in 8 countries. We defined eOGO as obstruction >25% in the cross-sectional area in imaging (percutaneous angiography, computed tomography, or intravascular ultrasound). The prevalence and annual incidence were calculated. Serious adverse events and outcomes (death, transplantation, or device exchange) were analyzed for eOGO cases.
RESULTS: Of 2108 patients, 62 were diagnosed with eOGO at a median LVAD support duration of 953 (interquartile range, 600-1267) days. The prevalence of eOGO was 3.0% and the incidence at 1, 2, 3, 4, and 5 years of support was 0.6%, 2.8%, 4.0%, 5.2%, and 9.1%, respectively. Of 62 patients, 9 were observed, 27 underwent surgical revision, 15 underwent percutaneous stent implantation, 8 received a heart transplant, and 2 died before intervention. One patient underwent surgical revision and later stent implantation. The mortality with therapeutic intervention was 9/53 (17.0%).
CONCLUSIONS: Although uncommon, HM 3 LVAD-supported patients might develop eOGO with an increasing incidence after 1 year of support. Although engineering efforts to reduce this complication are under way, clinicians must maintain a focus on early detection and remain vigilant.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:167 |
|---|---|
| Enthalten in: |
The Journal of thoracic and cardiovascular surgery - 167(2024), 4 vom: 15. März, Seite 1322-1330.e6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wert, Leonhard [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
HeartMate 3 |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jtcvs.2022.09.051 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350740143 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350740143 | ||
| 003 | DE-627 | ||
| 005 | 20240315232605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtcvs.2022.09.051 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM350740143 | ||
| 035 | |a (NLM)36562497 | ||
| 035 | |a (PII)S0022-5223(22)01042-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wert, Leonhard |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A multicenter evaluation of external outflow graft obstruction with a fully magnetically levitated left ventricular assist device |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The American Association for Thoracic Surgery. All rights reserved. | ||
| 520 | |a BACKGROUND: The HeartMate 3 (HM 3; Abbott) left ventricular assist device (LVAD) has improved hemocompatibility-related adverse outcomes. In sporadic cases, external compression of the outflow graft causing obstruction (eOGO) can result from substance accumulation between the outflow graft and its bend relief. We sought to evaluate the prevalence, course, and clinical implications of eOGO in an international study | ||
| 520 | |a METHODS: A multicenter retrospective analysis of HM 3 LVADs implanted between November 2014 and April 2021 (n = 2108) was conducted across 17 cardiac centers in 8 countries. We defined eOGO as obstruction >25% in the cross-sectional area in imaging (percutaneous angiography, computed tomography, or intravascular ultrasound). The prevalence and annual incidence were calculated. Serious adverse events and outcomes (death, transplantation, or device exchange) were analyzed for eOGO cases | ||
| 520 | |a RESULTS: Of 2108 patients, 62 were diagnosed with eOGO at a median LVAD support duration of 953 (interquartile range, 600-1267) days. The prevalence of eOGO was 3.0% and the incidence at 1, 2, 3, 4, and 5 years of support was 0.6%, 2.8%, 4.0%, 5.2%, and 9.1%, respectively. Of 62 patients, 9 were observed, 27 underwent surgical revision, 15 underwent percutaneous stent implantation, 8 received a heart transplant, and 2 died before intervention. One patient underwent surgical revision and later stent implantation. The mortality with therapeutic intervention was 9/53 (17.0%) | ||
| 520 | |a CONCLUSIONS: Although uncommon, HM 3 LVAD-supported patients might develop eOGO with an increasing incidence after 1 year of support. Although engineering efforts to reduce this complication are under way, clinicians must maintain a focus on early detection and remain vigilant | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HeartMate 3 | |
| 650 | 4 | |a left ventricular assist device | |
| 650 | 4 | |a outflow graft obstruction | |
| 700 | 1 | |a Stewart, Garrick C |e verfasserin |4 aut | |
| 700 | 1 | |a Mehra, Mandeep R |e verfasserin |4 aut | |
| 700 | 1 | |a Milwidsky, Assi |e verfasserin |4 aut | |
| 700 | 1 | |a Jorde, Ulrich P |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a Selzman, Craig H |e verfasserin |4 aut | |
| 700 | 1 | |a Stehlik, Josef |e verfasserin |4 aut | |
| 700 | 1 | |a Alshamdin, Faisal D |e verfasserin |4 aut | |
| 700 | 1 | |a Khaliel, Feras H |e verfasserin |4 aut | |
| 700 | 1 | |a Gustafsson, Finn |e verfasserin |4 aut | |
| 700 | 1 | |a Boschi, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Loforte, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Ajello, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Scandroglio, Anna M |e verfasserin |4 aut | |
| 700 | 1 | |a Tučanová, Zuzana |e verfasserin |4 aut | |
| 700 | 1 | |a Netuka, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Schlöglhofer, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Zimpfer, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Zijderhand, Casper F |e verfasserin |4 aut | |
| 700 | 1 | |a Caliskan, Kadir |e verfasserin |4 aut | |
| 700 | 1 | |a Dogan, Günes |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitto, Jan D |e verfasserin |4 aut | |
| 700 | 1 | |a Maier, Sven |e verfasserin |4 aut | |
| 700 | 1 | |a Schibilsky, David |e verfasserin |4 aut | |
| 700 | 1 | |a Jawad, Khalil |e verfasserin |4 aut | |
| 700 | 1 | |a Saeed, Diyar |e verfasserin |4 aut | |
| 700 | 1 | |a Faerber, Gloria |e verfasserin |4 aut | |
| 700 | 1 | |a Morshuis, Michiel |e verfasserin |4 aut | |
| 700 | 1 | |a Hanuna, Maja |e verfasserin |4 aut | |
| 700 | 1 | |a Müller, Christoph S |e verfasserin |4 aut | |
| 700 | 1 | |a Mulzer, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Kempfert, Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Falk, Volkmar |e verfasserin |4 aut | |
| 700 | 1 | |a Potapov, Evgenij V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of thoracic and cardiovascular surgery |d 1959 |g 167(2024), 4 vom: 15. März, Seite 1322-1330.e6 |w (DE-627)NLM000033510 |x 1097-685X |7 nnns |
| 773 | 1 | 8 | |g volume:167 |g year:2024 |g number:4 |g day:15 |g month:03 |g pages:1322-1330.e6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtcvs.2022.09.051 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 167 |j 2024 |e 4 |b 15 |c 03 |h 1322-1330.e6 | ||